Characterization and optimization of the glucan particle-based vaccine platform. - Wikidata - wikimedia - TriplyDB

Characterization and optimization of the glucan particle-based vaccine platform.

Characterization and optimization of the glucan particle-based vaccine platform.

http://www.wikidata.org/entity/Q37252339

about

Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome Host immunity to Cryptococcus neoformans Recent advances in oral vaccine development: yeast-derived β-glucan particles Beta-glucan contamination of pharmaceutical products: How much should we accept?Oxidation by neutrophils-derived HOCl increases immunogenicity of proteins by converting them into ligands of several endocytic receptors involved in antigen uptake by dendritic cells and macrophages Fungal vaccines and immunotherapeutics.Exploiting fungal cell wall components in vaccines A population of Langerin-positive dendritic cells in murine Peyer's patches involved in sampling β-glucan microparticles.Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts.Scaffolded Antigens in Yeast Cell Particle Vaccines Provide Protection against Systemic Polyoma Virus Infection.Targeted Delivery of Glucan Particle Encapsulated Gallium Nanoparticles Inhibits HIV Growth in Human Macrophages.Immune Response to Coccidioidomycosis and the Development of a Vaccine.Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines.Lung cancer and β-glucans: review of potential therapeutic applications.Duality of β-glucan microparticles: antigen carrier and immunostimulants.Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species.Modulating host immune responses to fight invasive fungal infections.Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.Beta-Glucan Particles as Vaccine Adjuvant Carriers.Interactions of Cryptococcus with Dendritic Cells.Vaccination with an alkaline extract of Histoplasma capsulatum packaged in glucan particles confers protective immunity in mice.

P2860

Q26767978-1952ADC5-C6A1-408D-A938-D144EF3E74D5 Q26823438-C09375BD-E50A-4BFF-BD3C-81DB0EC164AF Q27001699-60EA5246-5237-48C2-896A-6CE97CA859EB Q28077957-B20A4629-19EA-49C4-B4A9-C94AB22BE8ED Q28391399-90FA7880-FBA3-4ED9-B803-FC90C61E426C Q34400249-723D9630-E4AF-43A3-89D4-E5492A5412D4 Q35085200-B2B9DE2A-377E-4CB7-B514-270CEDF27EA3 Q35121693-5F1E079F-566D-418E-B867-9F43969A4459 Q36431583-676A1EF7-9BE0-4AB3-B44B-D7883581CBF8 Q36885774-9C9650E6-DB81-4CC3-8E69-C6C687204A90 Q37443661-FA7E974D-D131-45AF-A901-51EA50D0F19C Q37731260-9B338426-CA93-411F-9790-FD412CF165ED Q38671575-C629AB89-B042-47F9-95D3-EC99BED677D8 Q39183310-3250DF7F-2CF9-4B47-9976-AED4A73981C8 Q40688473-F2642C97-BFF9-401C-8D5C-5C6D28396764 Q46252449-A71BA34C-5372-40DB-8C59-0C72B09AB2CF Q46673081-3D87DBA6-6027-4BC0-A9DA-69EC471D6872 Q47563994-AC85DC81-1BA8-442B-A61B-BEAFFB13CAA2 Q50957928-D1F5CFB0-ED5F-4C91-9732-79CFFFBFCEDE Q52654069-C3A1118D-0C04-4F0B-8EAA-80D99ED85364 Q54220336-C07F0379-DFD1-4802-884A-E296C9D90EE2

P2860

Characterization and optimization of the glucan particle-based vaccine platform.

http://www.wikidata.org/entity/Q37252339

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Characterization and optimization of the glucan particle-based vaccine platform.

@en

Characterization and optimization of the glucan particle-based vaccine platform.

@nl

type

label

Characterization and optimization of the glucan particle-based vaccine platform.

@en

Characterization and optimization of the glucan particle-based vaccine platform.

@nl

prefLabel

Characterization and optimization of the glucan particle-based vaccine platform.

@en

Characterization and optimization of the glucan particle-based vaccine platform.

@nl

P1433

Q37252339-839CA488-A3A4-4535-A829-910F3E9EB47C

P1476

Q37252339-0AB31423-38C2-4AA4-9050-4D9604BB1878

P2093

Q37252339-15E41C0B-66E6-48D7-A084-B209E64B156C

Q37252339-363DD5E9-7DBF-428D-B0C3-D5E9A7E72BB1

Q37252339-39A80BC7-29FB-417B-AB40-29DE521A22E4

Q37252339-68A1B0CE-308E-4F8C-81EA-2224B2C727D9

Q37252339-CCD36F1D-0DD9-4B30-AA95-CC41345AA04E

P2860

Q37252339-013A7C5A-9C60-46AE-9A82-1C7A1CB1538F

Q37252339-07DB9867-0BFF-4575-8A88-C255A6AFB186

Q37252339-26C1B8FD-91A2-428D-8C43-214EBF421D39

Q37252339-3A03DC93-D792-474F-8021-08683D1E5C9D

Q37252339-51061956-EB64-4C6D-8126-0363903748A2

Q37252339-58769A4B-03E1-4854-A1BD-CA80E8D005B1

Q37252339-663F4C63-5100-4BD7-AB68-A1C87B3F447C

Q37252339-6A9DD97D-3219-4D40-B8DA-14AA3019BD5F

Q37252339-7023B0A1-B2B7-415B-8833-4547FA3CC217

Q37252339-79B910BE-F368-444E-BC73-492495A49676

P304

Q37252339-DDEA61BB-D189-4D0E-A8C0-8E99645A755D

P31

Q37252339-5C7993D2-9669-459D-82B3-E8830420C01A

P356

Q37252339-57433B89-93EA-456F-B457-1828AE857D60

P433

Q37252339-5AB0F073-E08F-4F93-9EB1-B77495AFECBA

P478

Q37252339-061A37D4-BE05-4CE4-9424-2915B7587B55

P577

Q37252339-F23A8155-0EFB-47BF-88FC-0A4BC3B0FBA6

P698

Q37252339-C4232EFA-6B6D-48F6-9405-0897FAB58A9F

P932

Q37252339-3226B9DE-BB02-402C-A067-6BF879CDD578

P356

P1433

Clinical and Vaccine Immunology

P1476

Characterization and optimization of the glucan particle-based vaccine platform.

@en

P2093

Charles A Specht

http://www.w3.org/2001/XMLSchema#string

Chrono K Lee

http://www.w3.org/2001/XMLSchema#string

Gary R Ostroff

http://www.w3.org/2001/XMLSchema#string

Haibin Huang

http://www.w3.org/2001/XMLSchema#string

Stuart M Levitz

http://www.w3.org/2001/XMLSchema#string

P2860

Beyond empiricism: informing vaccine development through innate immunity research

Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan

Immune recognition. A new receptor for beta-glucans

Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models

Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles

A novel adjuvant for vaccine development in the aged

The structure and synthesis of the fungal cell wall.

T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters.

Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans

Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis.

P304

1585-1591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00463-13

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23945157

http://www.w3.org/2001/XMLSchema#string

P932

3807193

http://www.w3.org/2001/XMLSchema#string